You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial

Article metrics

Article menu

Download PDFPDF

XML
Interstitial lung disease
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial

 

Online download statistics by month:

Online download statistics by month: September 2018 to March 2024

AbstractFullPdf
Sep 2018364362248
Oct 2018247271131
Nov 2018133134107
Dec 2018889094
Jan 20199386100
Feb 2019736699
Mar 2019989073
Apr 2019978767
May 2019727256
Jun 2019686746
Jul 201910410168
Aug 201913012465
Sep 201911010661
Oct 2019217192212
Nov 201915013788
Dec 2019127113105
Jan 20201069282
Feb 202014713354
Mar 2020907636
Apr 2020554827
May 2020706661
Jun 2020756851
Jul 2020867621
Aug 2020656125
Sep 202011911426
Oct 20201038467
Nov 20201059832
Dec 2020928539
Jan 2021665728
Feb 2021615423
Mar 20211058943
Apr 2021575128
May 2021625743
Jun 2021484329
Jul 2021545139
Aug 2021453925
Sep 2021464137
Oct 2021685847
Nov 2021393528
Dec 2021563928
Jan 2022433727
Feb 2022494321
Mar 2022463443
Apr 20221079727
May 2022635231
Jun 2022564321
Jul 2022513516
Aug 2022484719
Sep 202210310165
Oct 2022615917
Nov 2022615730
Dec 2022525012
Jan 2023423914
Feb 2023494029
Mar 2023524812
Apr 2023292719
May 2023363612
Jun 2023302313
Jul 2023231511
Aug 202328238
Sep 2023412914
Oct 2023453914
Nov 2023323119
Dec 2023968117
Jan 2024391612
Feb 2024403713
Mar 2024444490
Total535748963165